10 Devices that Could Pose Problems for Patients with ICDs

In a subanalysis of the SELECT trial, semaglutide was associated with reduction in MACE across weight and waist circumference categories, independent of body fat.

Today's episode covers depression risk after chronic illness, vaginal estradiol safety, GLP-1 updates, cancer risk, and cardiovascular outcomes.

The first FDA-approved oral GLP-1 receptor agonist received an expanded indication for both primary and secondary prevention in T2D patients at elevated CV risk.

This week’s podcast episode covers CRC screening, GLP-1 eligibility in youth, women’s heart health, FIT outreach, and ultraprocessed food risks.

Managing post–MI distress is no longer optional—it’s essential to comprehensive cardiac recovery, according to a new AHA statement.

Based on the PREVENT algorithm's estimates of 10-year ASCVD risk, 4.2 million adults may need to be reevaluated for aspirin discontinuation, authors reported.